Company profile
RELMADA THERAPEUTICS, INC.
NASDAQ:RLMDBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Esmethadone | phase3 | — | 6 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07313891 | phase3 | withdrawn | 2026-05-01 | 2029-09-01 | Relmada Therapeutics, Inc. | A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT |
| NCT07464145 | phase3 | not_yet_recruiting | 2027-02-01 | 2029-12-01 | Relmada Therapeutics, Inc. | A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer |
| NCT07342517 | phase3 | withdrawn | 2026-06-30 | 2027-06-30 | Relmada Therapeutics, Inc. | A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy |
| NCT04688164 | phase3 | completed | 2021-01-08 | 2022-11-01 | Relmada Therapeutics, Inc. | A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) |
| NCT05081167 | phase3 | completed | 2021-06-02 | 2022-09-13 | Relmada Therapeutics, Inc. | A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) |
FDA applications (0)
No records yet.